Literature DB >> 18562476

Stimulation of intramembranous bone repair in rats by ghrelin.

Feilong Deng1, Junqi Ling, Jiangyuan Ma, Chenhan Liu, Weizhen Zhang.   

Abstract

Researchers in our laboratory have previously shown that ghrelin, a gastric peptide hormone, may regulate mesenchymal cell differentiation into adipocytes and myocytes. Here we show that ghrelin promotes osteogenesis of intramembranous bone and improves the repair of calvarial bone defects in rats. Rats with a 9 mm full-thickness calvarial bone defect received either Bio-Oss (control group) or Bio-Oss mixed with 20 mug ghrelin (treatment group), followed by local administration of saline or ghrelin (10 microg), respectively, on days 5, 10 and 15. After 6 and 12 weeks, new bone formation was assessed. Animals treated with ghrelin showed a significant increase in new bone formation as demonstrated by an increment in bone mineral density and fluorescence labelling of tetracycline relative to the control group. At 6 weeks, bone mineral density increased from 54 +/- 7 (control group) to 78 +/- 9 mg cm(-2) in the treatment group, while the tetracycline fluorescence labelling increased by 61 +/- 15%. A similar increment was observed at 12 weeks. Quantitative reverse transcriptase-polymerase chain reaction showed that expression of alkaline phosphatase (ALP), osteocalcin and collagen type I was elevated. Relative to the control animals, mRNAs for ALP, osteocalcin and collagen type I increased 2.4 +/- 0.4-, 4.7 +/- 1.9- and 4.0 +/- 1.7-fold, respectively, in animals treated with ghrelin for 6 weeks (P < 0.05). At 12 weeks, mRNA levels of ALP, osteocalcin and collagen type I showed a decline relative to levels at 6 weeks but still remained significantly higher than in the control group, with fold changes of 2.4 +/- 0.8, 2.4 +/- 1.2 and 2.1 +/- 0.7, respectively (P < 0.05). This study demonstrated that ghrelin stimulates intramembranous osteogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562476     DOI: 10.1113/expphysiol.2007.041962

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  8 in total

Review 1.  Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass.

Authors:  M P Hage; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-09-06       Impact factor: 4.507

Review 2.  Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.

Authors:  S Epstein; G Defeudis; S Manfrini; N Napoli; P Pozzilli
Journal:  Osteoporos Int       Date:  2016-03-15       Impact factor: 4.507

3.  Ghrelin levels in chronic periodontitis patients.

Authors:  Gülin Yılmaz; Fatma Yeşim Kırzıoğlu; Duygu Kumbul Doğuç; Havva Koçak; Hikmet Orhan
Journal:  Odontology       Date:  2013-01-05       Impact factor: 2.634

4.  Ghrelin promotes differentiation of human embryonic stem cells into cardiomyocytes.

Authors:  Jin Yang; Guo-qiang Liu; Rui Wei; Wen-fang Hou; Mei-juan Gao; Ming-xia Zhu; Hai-ning Wang; Gui-an Chen; Tian-pei Hong
Journal:  Acta Pharmacol Sin       Date:  2011-08-01       Impact factor: 6.150

5.  Regulation of food intake and body weight by recombinant proghrelin.

Authors:  Weizhen Zhang; Arundhati Majumder; Xiaobin Wu; Michael W Mulholland
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-09-29       Impact factor: 4.310

Review 6.  Structure and physiological actions of ghrelin.

Authors:  Christine Delporte
Journal:  Scientifica (Cairo)       Date:  2013-11-28

7.  Preclinical therapies to prevent or treat fracture non-union: A systematic review.

Authors:  Philippa M Bennett; Sarah K Stewart; Janine Dretzke; Danai Bem; Jowan G Penn-Barwell
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

8.  Prevention of Bone Loss in a Model of Postmenopausal Osteoporosis through Adrenomedullin Inhibition.

Authors:  Sonia Martínez-Herrero; Ignacio M Larrayoz; Laura Ochoa-Callejero; Luis J Fernández; Alexis Allueva; Ignacio Ochoa; Alfredo Martínez
Journal:  Front Physiol       Date:  2016-06-30       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.